The prognostic significance of p16 expression pattern in diffuse gliomas

키워드

참고문헌 (36)

1. Foulkes WD, "The CDKN2A(p16)gene and human cancer", Mol Med, 3, pp.5~20 (1997)
2. Serrano M, "The tumor suppressor protein p16INK4a", Exp Cell Res, 237, pp.7~13 (1997)
3. Raschke S, "Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines", Genes Chromosomes Cancer, 42, pp.58~67 (2005)
4. Appay R, "CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas", Neuro Oncol, 21, pp.1519~1528 (2019)
5. Reis GF, "CDKN2A loss is associated with shortened overall survival in lower-grade(World Health Organization Grades II-III)astrocytomas", J Neuropathol Exp Neurol, 74, pp.442~452 (2015)
6. Shirahata M, "Novel, improved grading system(s)for IDH-mutant astrocytic gliomas", Acta Neuropathol, 136, pp.153~166 (2018)
7. Yang RR, "IDH mutant lower grade(WHO Grades II", III)astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations, 2020, pp.30, 541~553
8. Aoki K, "Prognostic relevance of genetic alterations in diffuse lower-grade gliomas", Neuro Oncol, 20, pp.66~77 (2018)
9. Brat DJ, "cIMPACT-NOW update 5 : recommended grading criteria and terminologies for IDH-mutant astrocytomas", Acta Neuropathol, 139, pp.603~608 (2020)
10. Louis DN, "cIMPACT-NOW update 6 : new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading", Brain Pathol, 30, pp.844~856 (2020)
11. Frazao L, "BRAF V600E mutation and 9p21 : CDKN2A", B and MTAP co-deletions : markers in the clinical stratification of pediatric gliomas, 2018, pp.18, 1259~
12. Miettinen H, "CDKN2", p16 predicts survival in oligodendrogliomas : comparison with astrocytomas, 1999, pp.41, 205~211
13. Bortolotto S, "CDKN2A", p16 inactivation in the prognosis of oligodendrogliomas, 2000, pp.88, 554~557
14. Kirla R, "Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy", J Neurooncol, 46, pp.71~80 (2000)
15. Jeon YK, "Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors : a clinicopathological study using fluorescence in situ hybridization", Neuropathology, 27, pp.10~20 (2007)
16. Puduvalli VK, "Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival", Int J Oncol, 17, pp.963~969 (2000)
17. Arifin MT, "Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas", J Neurooncol, 77, pp.273~277 (2006)
18. Milde-Langosch K, "Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype", Breast Cancer Res Treat, 67, pp.61~70 (2001)
19. O’Neill CJ, "p16 expression in the female genital tract and its value in diagnosis", Adv Anat Pathol, 13, pp.8~15 (2006)
20. Lam AK, "p16 expression in colorectal adenocarcinoma : marker of aggressiveness and morphological types", Pathology, 40, pp.580~585 (2008)
21. Romagosa C, "p16(Ink4a)overexpression in cancer : a tumor suppressor gene associated with senescence and high-grade tumors", Oncogene, 30, pp.2087~2097 (2011)
22. Ajay Chaurasia, "Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival", Journal of Korean Medical Science, 31(8), pp.1208~1214 (2016), 대한의학회
23. Koh J, "IDH2 mutation in gliomas including novel mutation", Neuropathology, 35, pp.236~244 (2015)
24. 김성익, "Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach", Journal of Pathology and Translational Medicine, 52(1), pp.28~36 (2018), 대한병리학회[DOI]
25. Chung CT, "FISH assay development for the detection of p16", CDKN2A deletion in malignant pleural mesothelioma, 2010, pp.63, 630~634
26. Berger AH, "A continuum model for tumour suppression", Nature, 476, pp.163~169 (2011)
27. Lotan TL, "Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH", Mod Pathol, 29, pp.904~914 (2016)
28. Lu VM, "The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma : a systematic review of the contemporary literature", J Neurooncol, 148, pp.221~229 (2020)
29. Burns KL, "Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas", J Neuropathol Exp Neurol, 57, pp.122~130 (1998)
30. Purkait S, "CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry", Neuropathology, 33, pp.405~412 (2013)
31. Purkait S, "EZH2 expression in gliomas : correlation with CDKN2A gene deletion", p16 loss and MIB-1 proliferation index, 2015, pp.35, 421~431
32. Fuller CE, "Fluorescence in situ hybridization(FISH)in diagnostic and investigative neuropathology", Brain Pathol, 12, pp.67~86 (2002)
33. Chiosea S, "Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas", Mod Pathol, 21, pp.742~747 (2008)
34. Piva R, "CDKN2", p16 inactivation and p16 immunohistochemistry in astrocytic gliomas, 1998, pp.12, 55~58
35. Noushmehr H, "Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma", Cancer Cell, 17, pp.510~522 (2010)
36. Nakamura M, "Promoter hypermethylation of the RB1 gene in glioblastomas", Lab Invest, 81, pp.77~82 (2001)

관련 논문AI추천